KR100533304B1 - Polyethoxylated alpha tocopherol ester derivatives and process for preparing the same - Google Patents

Polyethoxylated alpha tocopherol ester derivatives and process for preparing the same Download PDF

Info

Publication number
KR100533304B1
KR100533304B1 KR10-2001-0029223A KR20010029223A KR100533304B1 KR 100533304 B1 KR100533304 B1 KR 100533304B1 KR 20010029223 A KR20010029223 A KR 20010029223A KR 100533304 B1 KR100533304 B1 KR 100533304B1
Authority
KR
South Korea
Prior art keywords
formula
compound
alpha
feed
vitamin
Prior art date
Application number
KR10-2001-0029223A
Other languages
Korean (ko)
Other versions
KR20020090048A (en
Inventor
정봉열
박봉준
김영근
Original Assignee
주식회사 엘지생명과학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘지생명과학 filed Critical 주식회사 엘지생명과학
Priority to KR10-2001-0029223A priority Critical patent/KR100533304B1/en
Publication of KR20020090048A publication Critical patent/KR20020090048A/en
Application granted granted Critical
Publication of KR100533304B1 publication Critical patent/KR100533304B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/723,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols

Abstract

본 발명은 동물용 사료 첨가제로 유용한 다음 화학식 1로 표시되는 신규한 폴리에톡실화 알파 토코페롤 에스테르 유도체 및 이의 제조방법에 관한 것이다:The present invention relates to a novel polyethoxylated alpha tocopherol ester derivative represented by the following general formula (1) useful as an animal feed additive and a method for preparing the same:

[화학식 1][Formula 1]

상기 식에서,Where

R은 CH3OCH2CH2(OCH2CH2)n이며, 여기서 n은 2∼400의 정수이다.R is CH 3 OCH 2 CH 2 (OCH 2 CH 2 ) n, where n is an integer from 2 to 400.

Description

폴리에톡실화 알파 토코페롤 에스테르 유도체 및 이의 제조방법{Polyethoxylated alpha tocopherol ester derivatives and process for preparing the same}Polyethoxylated alpha tocopherol ester derivatives and process for preparing the same}

본 발명은 신규의 폴리에톡실화 알파 토코페롤 에스테르 유도체 및 이의 제조방법에 관한 것이다. 폴리에톡실화 알파 토코페롤 에스테르 유도체는 구체적으로 DL-알파-토코페릴-ω-메톡시폴리에틸렌글리코릴-석시네이트 유도체로 언급될 수 있다.The present invention relates to novel polyethoxylated alpha tocopherol ester derivatives and methods for their preparation. Polyethoxylated alpha tocopherol ester derivatives may be specifically referred to as DL-alpha-tocopheryl-ω-methoxypolyethyleneglycolyl-succinate derivatives.

하기 화학식 2로 표시되는 비타민 E(DL-알파-토코페롤)은 생명체에 항산화제로 널리 사용되며, 최근 들어 임상적용 분야가 확장되고 있고, 이에 대한 요구도 증가하고 있는 추세이다:Vitamin E (DL-alpha-tocopherol) represented by the following Chemical Formula 2 is widely used as an antioxidant in living organisms, and recently, the field of clinical application is expanding, and the demand for this is increasing:

[화학식 2][Formula 2]

비타민 E는 벤젠고리에 하이드록시기를 가지고 있는 화합물로써 물리적으로는 물에 용해되지 않는 지용성의 특징이 있고, 비타민 E 자체는 일반적으로 산화가 잘 되기 때문에 화학적으로 불안정할 뿐만 아니라 산화 생성물인 토코페롤 퀴논은 비타민 E의 생물학적 활성을 갖지 못한다. 따라서, 비타민 E의 산화를 방지하기 위하여 보다 안정화 된 유도체들로 전환시켜 사용하는데, 이러한 유도체들로는 초산 토코페롤, 팔미틴산 토코페롤, 호박산 토코페롤 등이 있다. 이들은 비타민 E 자체에 비해 비교적 안정도가 높기 때문에 보관 및 수송상의 장점을 가지고 있고, 약물학적인 목적으로는 허용 가능한 안정도를 가지고 있기 때문에 비타민 E의 대체물 제조용으로 효과적이다.Vitamin E is a compound having a hydroxy group in the benzene ring, which is physically insoluble in water, and because vitamin E itself is generally oxidized, it is not only chemically unstable but also an oxidation product of tocopherol quinone. Does not have the biological activity of vitamin E. Therefore, in order to prevent the oxidation of vitamin E is converted to more stabilized derivatives, such derivatives include tocopherol acetate, palmitate tocopherol, succinate tocopherol and the like. They have advantages of storage and transport because of their relatively high stability compared to vitamin E itself, and are effective for the manufacture of substitutes for vitamin E because of their acceptable stability for pharmacological purposes.

또한 경구 투여의 경우에 있어서, 상술한 비타민 E 에스테르 화합물들은 생체내의 장관을 통해 흡수될 때, 췌액 효소 및 장효소와 접촉하면 완전히 가수분해 되어 토코페롤 형태로 생체 내에 흡수된다.In addition, in the case of oral administration, the vitamin E ester compounds described above are completely hydrolyzed upon contact with pancreatic enzymes and intestinal enzymes when absorbed through the intestinal tract in vivo, and are absorbed in vivo in the form of tocopherols.

이러한 이유로 전 축(畜)종 모든 사료에 비타민 E 대체물을 많이 사용하고 있으며, 특히 양돈사료에 비타민 E 공급원으로 초산 토코페롤을 널리 사용하고 있고, 돈육의 육질 개선제로서의 효과가 있는 것으로 널리 알려지고 있다.For this reason, vitamin E substitutes are widely used in all feedstocks, and tocopherol acetate is widely used as a source of vitamin E in pig feed, and it is widely known that it is effective as a meat improver of pork.

이에, 본 발명자들은 상기에 언급된 비타민 E의 최대 단점인 화학적인 불안정성 및 물에 대한 난용성 문제를 개선하고, 초산 토코페롤 보다 효과가 우수한 물질을 개발하고자 연구를 계속한 결과, 본 발명에 따른 폴리에톡실화 알파 토코페롤 에스테르 유도체들은 물에 대한 용해도가 크고, 산화가 잘되지 않고 화학적으로 안정도를 가지고 있다는 사실을 밝혀냈다. 그리고 기존의 양돈사료에 비타민 E 공급원으로 현재 널리 사용되고 있는 초산 토코페롤과 위 화합물과의 효능비교시험 결과 돈육의 육질개선 뿐만 아니라 증체 효과까지 있음을 새롭게 밝혀내고 본 발명을 완성하게 되었다.Accordingly, the present inventors have continued research to improve the chemical instability and the poor solubility in water, the most disadvantage of vitamin E mentioned above, and to develop a material that is more effective than tocopherol acetate, the poly according to the present invention Ethoxylated alpha tocopherol ester derivatives were found to be highly soluble in water, poorly oxidized and chemically stable. In addition, as a result of comparing efficacy of the above compound with tocopherol acetate, which is currently widely used as a source of vitamin E in pig feed, it has been newly found that not only meat improvement but also an increase effect of pork is completed.

따라서, 본 발명의 목적은 신규의 폴리에톡실화 알파 토코페롤 에스테르 유도체와 이의 제조방법을 제공하는 것이다.It is therefore an object of the present invention to provide novel polyethoxylated alpha tocopherol ester derivatives and methods for their preparation.

본 발명의 폴리에톡실화 알파 토코페롤 에스테르 유도체는 다음 화학식 1로 표시된다:The polyethoxylated alpha tocopherol ester derivatives of the present invention are represented by the following general formula (1):

[화학식 1][Formula 1]

상기 식에서,Where

R은 CH3OCH2CH2(OCH2CH2)n이며, 여기서 n은 2∼400의 정수이다.R is CH 3 OCH 2 CH 2 (OCH 2 CH 2 ) n, where n is an integer from 2 to 400.

상기 화학식 1의 화합물중 바람직한 그룹은 n이 2∼50의 정수인 R의 그룹을 가진 화합물이다.Preferred groups in the compound of Formula 1 are those having a group of R where n is an integer from 2 to 50.

화학식 1의 화합물중 가장 바람직한 그룹은 DL-알파-토코페릴-ω-메틸 폴리에틸렌글라이코릴-석시네이트 (n=6); DL-알파-토코페릴-ω-메틸 폴리에틸렌글라이코릴-석시네이트 (n=11); DL-알파-토코페릴-ω-메틸 폴리에틸렌글라이코릴-석시네이트 (n=44)중에서 선택된다.Most preferred groups of compounds of formula (1) are DL-alpha-tocopheryl-ω-methyl polyethyleneglycoryl-succinate (n = 6); DL-alpha-tocopheryl-ω-methyl polyethyleneglycolyl-succinate (n = 11); DL-alpha-tocopheryl-ω-methyl polyethyleneglycolyl-succinate (n = 44).

상기 화학식 1의 화합물은 분리된 개별적인 혼합물 또는 단일 화합물을 모두 포함한다. 또한, 생물학적 연구에 적합한 화학식 1의 화합물에 방사성 표지한 화합물도 본 발명의 범위에 포함된다.The compound of Formula 1 includes all of the separated individual mixtures or single compounds. Also included in the scope of the invention are compounds that are radiolabeled to a compound of formula 1 suitable for biological research.

상기 화학식 1의 화합물은 다음 화학식 3의 화합물(DL-알파-토코페릴석시네이트)와 화학식 4의 화합물을 에스테르화 반응시켜 제조될 수 있다:The compound of Formula 1 may be prepared by esterifying a compound of Formula 3 (DL-alpha-tocopherylsuccinate) with a compound of Formula 4:

[화학식 3][Formula 3]

[화학식 4][Formula 4]

R-OHR-OH

상기 식에서, R은 상기에 정의한 바와 같다.Wherein R is as defined above.

상기 제조방법을 구체적으로 설명하면, 화학식 3의 화합물과 화학식 4의 화합물을 상온에서 적합한 불활성 용매, 예를들어 메틸렌디클로라이드, 아세토나이트릴, N,N-디메틸포름알데히드 또는 톨루엔중에서, 적합한 축합제, 예를들어 1,3-디사이클로헥실카보디이미드(DCC) 또는 파라톨루엔술폰산 및 적합한 촉매, 예를들어 N,N-디메틸-4-아미노피리딘과 같은 3차 아민류 존재하에서 반응시키는 것이다.Specifically, the process of preparing the compound of formula 3 and compound of formula 4 in a suitable inert solvent such as methylenedichloride, acetonitrile, N, N-dimethylformaldehyde or toluene at room temperature, suitable condensing agents For example 1,3-dicyclohexylcarbodiimide (DCC) or paratoluenesulfonic acid and a suitable catalyst such as N, N-dimethyl-4-aminopyridine in the presence of tertiary amines.

출발물질로서 사용된 상기 화학식 3의 화합물(DL-알파-토코페릴 석시네이트)은 알파-토코페릴을 유기반응용매인 N,N-디메틸포름알데히드와 포타슘 하이드록시드중에서 무수 석신산으로 처리하여 제조되며, 이미 공지된 물질이다.The compound of formula 3 (DL-alpha-tocopheryl succinate) used as a starting material was prepared by treating alpha-tocopheryl with anhydrous succinic acid in N, N-dimethylformaldehyde and potassium hydroxide as organic reaction solvents. And already known materials.

한편, 본 발명에서 사용된 화학식 4의 화합물로서는 R에서 n가 2∼400의 정수인 폴리에틸렌글라이콜 메틸 에테르가 언급될 수 있으나, n가 2∼50의 정수인 폴리에틸렌글라이콜 메틸 에테르가 바람직하다.Meanwhile, as the compound of formula 4 used in the present invention, polyethylene glycol methyl ether in which n is an integer of 2 to 400 may be mentioned, but polyethylene glycol methyl ether in which n is an integer of 2 to 50 is preferable.

상기 반응에서 화학식 4의 화합물은 화학식 3의 화합물을 기준으로 하여 0.8 내지 2.0 당량, 바람직하게는 0.8 내지 1.2 당량 사용한다. 축합제의 사용량은 화학식 3의 화합물 기준으로 0.8 내지 2.0 당량, 바람직하게는 0.9 내지 1.5 당량 사용한다. 촉매 사용량은 화학식 3의 화합물을 기준으로 하여 0.01 내지 1.1 당량, 바람직하게는 0.1 내지 1.0 당량 사용한다. 반응시간은 약 5 시간이 바람직하다.In the reaction, the compound of Formula 4 is used in an amount of 0.8 to 2.0 equivalents, preferably 0.8 to 1.2 equivalents, based on the compound of Formula 3. The amount of the condensing agent is used based on the compound of Formula 3, 0.8 to 2.0 equivalents, preferably 0.9 to 1.5 equivalents. The amount of the catalyst used is 0.01 to 1.1 equivalents, preferably 0.1 to 1.0 equivalents based on the compound of formula (3). The reaction time is preferably about 5 hours.

본 발명에 따른 폴리에톡실화 알파 토코페롤 에스테르 유도체는 물리적 및 화학적으로 다양한 특성을 지니고 있는 중성의 폴리에테르인 폴리에틸렌글리콜이 공유 결합된 신규의 폴리에톡실화 알파 토코페롤 에스테르 화합물이며, 이로서 동물용 사료첨가제로 널리 사용되고 있는 초산 토코페롤 보다 물에 대한 용해도가 크고, 특히 양돈사료의 첨가제로써 사용할 경우 돈육의 육질개선 뿐마 아니라 증체효과까지 있음을 이후 설명하는 실험예를 통해 확인할 수 있다.The polyethoxylated alpha tocopherol ester derivative according to the present invention is a novel polyethoxylated alpha tocopherol ester compound covalently bonded to polyethylene glycol, which is a neutral polyether having physically and chemically diverse properties, and thus is an animal feed additive. Solubility in water is greater than that of tocopherol acetate, which is widely used as an additive, and especially when used as an additive in pig feed, it can be confirmed through experimental examples that explain not only meat improvement but also a gain effect.

이와 같은 특징으로 인하여, 본 발명에 따른 화합물은 동물용 사료첨가제의 비타민 E 공급원으로 매우 우수한 화합물일 뿐만아니라, 저약량의 사용으로도 사료 효과를 극대화할 수 있다.Due to these characteristics, the compound according to the present invention is not only a very good compound as a vitamin E source of animal feed additives, but also maximizes the effect of feed with the use of low doses.

따라서, 화학식 1의 화합물은 동물용 사료첨가제로서 유용하게 사용될 수 있다.Therefore, the compound of formula 1 can be usefully used as a feed additive for animals.

본 발명에 따른 동물용 사료첨가제는 일반 사료에 그대로 배합하여 사용하거나, 사료용으로 허용되는 일반적인 부형제와 혼합하여 제제화한 다음 배합하여 사용할 수 있으며, 화학식 1 화합물의 사용량은 사료의 총중량을 기준으로 하여 비타민 E 농도가 보통 1 내지 500 ppm이고 바람직하게는 10 내지 200 ppm이다.Animal feed additives according to the present invention can be used as it is in a general feed or mixed with a general excipient that is acceptable for feed and then formulated and used in combination, the amount of the compound of formula 1 is based on the total weight of the feed vitamin The E concentration is usually 1 to 500 ppm and preferably 10 to 200 ppm.

본 발명의 사료 첨가제는 비타민 E 공급원으로서 동물용 또는 어류용 사료에 적합하다. 구체적으로 해당되는 가축은 소, 말, 돼지, 젖소, 양, 염소, 고양이, 개, 낙타와 같은 포유류, 밍크 및 친칠라와 같은 털을 가진 동물, 동물원에 있는 동물 및 마우스와 래트와 같은 실험용 동물; 거위, 닭, 칠면조, 오리, 비둘기와 같은 조류, 동물원 조류 및 앵무새와 잉꼬와 같은 실험실 조류; 잉어, 송어, 연어, 텐취 및 뱀장어와 같은 어류, 장식용 어류 및 수족관 어류; 악어 및 뱀과 같은 파충류이다.The feed additive of the present invention is suitable for animal or fish feed as a vitamin E source. Specifically, the livestock includes cattle, horses, pigs, cows, sheep, goats, cats, dogs, mammals such as camels, animals with hair such as mink and chinchillas, animals in zoos and laboratory animals such as mice and rats; Birds such as geese, chickens, turkeys, ducks, pigeons, zoo birds and laboratory birds such as parrots and macaws; Fish such as carp, trout, salmon, tenches and eel, ornamental fish and aquarium fish; It is a reptile such as crocodile and snake.

본 발명은 하기 실시예 및 실험예에 의해 더욱 구체적으로 설명되나 본 발명의 범위가 이들에 의해 어떤 식으로든 제한되는 것은 아니다.The present invention is explained in more detail by the following examples and experimental examples, but the scope of the present invention is not limited in any way by these.

실시예 1Example 1

DL-알파-토코페릴-ω-메틸 폴리에틸렌글라이코릴-석시네이트 (n=6)의 합성Synthesis of DL-alpha-tocopheryl-ω-methyl polyethyleneglycolyl-succinate (n = 6)

DL-알파-토코페릴석시네이트(5.3g, 0,01몰)을 메틸렌디클로라이드(20ml)에 용해시킨 후 폴리에틸렌글라이콜 메틸에테르(3.5g, 0.01몰, 평균분자량: 350, n=6), 4-(디메틸아미노피리딘(0.1g, 0.001몰), 디사이클로 헥실카보디이미드(2.7g, 0.13몰)를 가하여 상온에서 약 5시간 가량 반응시킨다. 반응이 종료되면 상기 반응액을 여과하고 1N-염산 수용액으로 세척, MgSO4로 건조, 감압하에서 용매를 제거하면 액상의 표제화합물(7.7g, 수율 90%)를 얻었다.DL-alpha-tocopherylsuccinate (5.3 g, 0,01 mole) was dissolved in methylene dichloride (20 ml) and then polyethylene glycol methyl ether (3.5 g, 0.01 mole, average molecular weight: 350, n = 6 ), 4- (dimethylaminopyridine (0.1 g, 0.001 mole) and dicyclo hexylcarbodiimide (2.7 g, 0.13 mole) are added and allowed to react for about 5 hours at room temperature. Washing with a 1N aqueous hydrochloric acid solution, drying with MgSO 4 and removing the solvent under reduced pressure gave the title compound (7.7 g, 90% yield) as a liquid.

1H NMR (300MHz CDCl3) : δ 0.82∼0.89(m,12H), 1.08∼1.74(m,26H), 1.98(s,3H), 2.03(s,3H), 2.09(s,3H), 2.57(t,2H), 2.78(t,2H), 2.94(t,2H), 3.38(s,3H), 3.56~3.60(m,26H), 4.29(2H) 1 H NMR (300MHz CDCl 3 ): δ 0.82-0.89 (m, 12H), 1.08-1.74 (m, 26H), 1.98 (s, 3H), 2.03 (s, 3H), 2.09 (s, 3H), 2.57 (t, 2H), 2.78 (t, 2H), 2.94 (t, 2H), 3.38 (s, 3H), 3.56 ~ 3.60 (m, 26H), 4.29 (2H)

분자량(M+1)+ : 855Molecular weight (M + 1) + : 855

용해도(물) : 0.2% (wt%) Solubility (Water): 0.2% (wt%)

실시예 2Example 2

DL-알파-토코페릴-ω-메틸 폴리에틸렌글라이코릴-석시네이트 (n=11)의 합성Synthesis of DL-alpha-tocopheryl-ω-methyl polyethyleneglycolyl-succinate (n = 11)

실시예 1의 폴리에틸렌글라이콜 메틸에테르(3.5g, 0.01몰, 평균분자량: 350, n=6) 대신 폴리에틸렌글라이콜 메틸에테르(5.5g, 0.01몰, 평균분자량: 550, n=11)을 사용하여 액상의 표제화합물(9.8g, 수율 92%)를 얻었다.Polyethylene glycol methyl ether (5.5 g, 0.01 mol, average molecular weight: 550, n = 11) was used instead of the polyethylene glycol methyl ether (3.5 g, 0.01 mol, average molecular weight: 350, n = 6) of Example 1. The title compound (9.8 g, yield 92%) was obtained using a liquid.

1H NMR (300MHz CDCl3) : δ0.82∼0.88(m,12H), 1.08∼1.75(m,26H), 1.97(s,3H), 2.02(s,3H), 2.09(s,3H), 2.58(t,2H), 2.79(t,2H), 2.94(t,2H), 3.38(s,3H), 3.54∼3.61(m,46H), 4.28(t,2H) 1 H NMR (300 MHz CDCl 3 ): δ 0.82-0.88 (m, 12H), 1.08-1.75 (m, 26H), 1.97 (s, 3H), 2.02 (s, 3H), 2.09 (s, 3H), 2.58 (t, 2H), 2.79 (t, 2H), 2.94 (t, 2H), 3.38 (s, 3H), 3.54-3.61 (m, 46H), 4.28 (t, 2H)

분자량(M+1)+ : 1075Molecular weight (M + 1) + : 1075

용해도(물) : 0.3% (wt%)Solubility (Water): 0.3% (wt%)

실시예 3Example 3

DL-알파-토코페릴-ω-메틸 폴리에틸렌글라이코릴-석시네이트 (n=44)의 합성Synthesis of DL-alpha-tocopheryl-ω-methyl polyethyleneglycolyl-succinate (n = 44)

실시예 1의 폴리에틸렌글라이콜 메틸에테르(3.5g, 0.01몰, 평균분자량: 350, n=6) 대신 폴리에틸렌글라이콜 메틸에테르(20.0g, 0.01몰, 평균분자량: 2000, n=44)을 사용하여 고상의 표제화합물(25.3g, 수율 90%)를 얻었다.Polyethylene glycol methyl ether (20.0 g, 0.01 mol, average molecular weight: 2000, n = 44) was used instead of the polyethylene glycol methyl ether (3.5 g, 0.01 mol, average molecular weight: 350, n = 6) of Example 1. The title compound (25.3 g, yield 90%) was obtained.

1H NMR (300MHz CDCl3) : δ0.82∼0.89(m,2H), 1.08∼1.76(m,26H), 1.96(s,3H), 2.01(s,3H), 2.08(s,3H), 2.56(t,2H), 2.78(t,2H), 2.93(t,2H), 3.37(s,3H), 3.45∼3.76(m,178H), 4.27(t,2H) 1 H NMR (300 MHz CDCl 3 ): δ 0.82 to 0.99 (m, 2H), 1.08 to 1.76 (m, 26H), 1.96 (s, 3H), 2.01 (s, 3H), 2.08 (s, 3H), 2.56 (t, 2H), 2.78 (t, 2H), 2.93 (t, 2H), 3.37 (s, 3H), 3.45-3.76 (m, 178H), 4.27 (t, 2H)

분자량(M+1)+ : 2527Molecular weight (M + 1) + : 2527

용해도(물) : 0.5% (wt%)Solubility (Water): 0.5% (wt%)

실험예 1. 비육돈의 성장과 도체품질에 미치는 영향평가Experimental Example 1. Evaluation of the effect on the growth and carcass quality of finishing pigs

표준 대조 화합물인 초산 토코페롤 대비 화학식 1의 화합물(실시예 2에서 제조된 화합물, n= 11)을 비육돈에 사료와 함께 투여시 비육돈의 성장과 도체품질에 미치는 영향을 구명하기 위하여 유효성 시험군의 체중, 사료 섭취량, 일당 증체량, 사료 요구율(사료섭취량/체중증대, 수치가 낮을수록 효율이 좋음) 및 도체등급을 측정 비교하였다.To examine the effect of the compound of formula 1 (compound prepared in Example 2, n = 11) compared to the standard control compound tocopherol on the growth and carcass quality of the finishing pigs when administered with the feed to the finishing pigs , Feed intake, weight gain per day, feed intake (feed intake / weight gain, lower values are more efficient) and carcass ratings were compared.

실험 동물의 수는 총 160수(5마리/우리(pen)), 평균 체중 78 ±2 kg(50두) 1 반복, 74 ±2 kg(50두) 2 반복, 70 ±2 kg(50두) 3 반복이며, 암수 비율은 처리간에 차이가 없도록 같은 비율로 조정하며, 삼원교잡종 비육돈을 사용하여 상기 실험을 실시하였다.The total number of test animals was 160 (5 / pen), average weight 78 ± 2 kg (50 heads) 1 repetition, 74 ± 2 kg (50 heads) 2 repetitions, 70 ± 2 kg (50 heads) Three repetitions, the male and female ratio was adjusted to the same ratio so that there is no difference between treatments, the experiment was carried out using ternary hybrid pigs.

1. 실험방법1. Experimental method

대상 축(畜)의 체중을 측정한 후 1 주일간 사료를 급여하면서 투쟁에 대한 순화과정을 1 주일 갖고 그 이후 다시 체중을 측정한 후 시험사료를 급여한다.After weighing the subject's shaft, feed is fed for one week, followed by a week of purifying the struggle, then weighed again, and then fed test feeds.

시험사료의 경우 비육돈 시험사료의 에너지 단백질을 맞춘 기초사료와 비타민 미네랄 혼합물만을 별도로 구입하되 비타민 E는 기존의 비타민 제제를 구입한다. 화합물 1의 화합물은 별도로 공급 받아 사료배합에 사용한다. 사료 및 물은 자유로이 섭취할 수 있도록 하였고, 총 6주간 사양시험을 실시하며 매 3주 간격으로 체중 및 사료 요구율을 측정한다. 시험 종료시 도축하고 등급판정을 받는다.In the case of the test feed, only the basic food and the vitamin-mineral mixture prepared with the energy protein of the hog test feed are purchased separately, but the vitamin E is purchased with the existing vitamin preparation. Compound 1 is supplied separately and used in feed formulations. Feed and water were allowed to be freely consumed, followed by a total of six weeks of specification testing, and body weight and feed requirements were measured every three weeks. Slaughter and graded at the end of the test.

2. 시험결과2. Test result

[표 1]TABLE 1

돼지에서의 유효성 시험결과 (n=15 두)Effectiveness test results in pigs (n = 15 two)

농도density 체중(kg)Weight (kg) 일당 증체량(kg/일)Weight gain per day (kg / day) 사료 섭취량(kg)Feed Intake (kg) 사료 요구율Feed requirement 0 주0 weeks 3 주3 weeks 6 주6 Weeks 0∼30 to 3 3∼63 to 6 0∼6주0-6 weeks 0∼30 to 3 3∼63 to 6 0-6주0-6 weeks 0∼30 to 3 3∼63 to 6 0∼6주0-6 weeks 초산 토코페롤10 ppmTocopherol Acetate 10 ppm 73.973.9 91.391.3 106.0106.0 0.830.83 0.700.70 0.760.76 43.343.3 47.347.3 90.690.6 2.512.51 3.243.24 2.832.83 초산 토코페롤 90 ppmTocopherol Acetate 90 ppm 71.771.7 88.288.2 103.4103.4 0.790.79 0.730.73 0.760.76 42.242.2 48.048.0 90.290.2 2.582.58 3.183.18 2.852.85 화학식 110 ppmFormula 110 ppm 70.870.8 88.988.9 104.8104.8 0.860.86 0.760.76 0.810.81 43.443.4 49.249.2 92.692.6 2.422.42 3.203.20 2.732.73 화학식 190 ppmFormula 190 ppm 71.571.5 90.290.2 106.8106.8 0.890.89 0.790.79 0.840.84 45.745.7 52.552.5 98.298.2 2.452.45 3.193.19 2.782.78

[표 2]TABLE 2

도체 등급 판정결과(n=15 두, 평균치)Conductor rating result (n = 15 two, average value)

투여방법Dosing method 생체중(kg)Live weight (kg) 도체중(kg)Conductor weight (kg) 도체중 비율(%)Conductor weight ratio (%) 등지방(mm)Back fat (mm) 도체 등급(%)Conductor rating (%) AA BB CC 초산 토코페롤Tocopherol Acetate 104.3104.3 79.079.0 75.975.9 19.519.5 48.948.9 42.242.2 8.98.9 화학식 1Formula 1 106.3106.3 80.180.1 75.475.4 18.518.5 53.353.3 42.242.2 4.44.4

본 발명의 화합물은 상기 실험예에서도 알 수 있듯이 동물용 사료에 비타민 E의 공급원으로 사용할 수 있고 특히 양돈사료에 있어서 기존에 널리 사용되고 있는 초산 토코페롤보다 돈육의 육질개선제의 효과가 월등하고, 초산토코페롤 사용시 기대할 후 없었던 체중증대 효과 및 사료 요구율을 극대화시킬 수 있으므로 전 축종 모든 사료에 비타민 E의 공급원으로 사용될 수 있다.The compound of the present invention can be used as a source of vitamin E in animal feed as can be seen in the above experimental example, and in particular, the effect of the meat improver of pork is superior to the conventionally widely used tocopherol acetate in pig feed, and when using tocopherol acetate It can be used as a source of vitamin E in all feeds because it can maximize the weight gain effect and feed requirements that were not expected.

Claims (4)

다음 화학식 1로 표시되는 폴리에톡실화 알파 토코페롤 에스테르 화합물:The polyethoxylated alpha tocopherol ester compound represented by the following formula (1): [화학식 1][Formula 1] 상기 식에서,Where R은 CH3OCH2CH2(OCH2CH2)n이며, 여기서 n은 2∼400의 정수이다.R is CH 3 OCH 2 CH 2 (OCH 2 CH 2 ) n, where n is an integer from 2 to 400. 제 1 항에 있어서, DL-알파-토코페릴-ω-메틸 폴리에틸렌글라이코릴-석시네이트 (n=6); DL-알파-토코페릴-ω-메틸 폴리에틸렌글라이코릴-석시네이트 (n=11); 및 DL-알파-토코페릴-ω-메틸 폴리에틸렌글라이코릴-석시네이트 (n=44)로 구성된 그룹중에서 선택되는 화합물.2. A compound according to claim 1, wherein DL-alpha-tocopheryl-ω-methyl polyethyleneglycolyl-succinate (n = 6); DL-alpha-tocopheryl-ω-methyl polyethyleneglycolyl-succinate (n = 11); And DL-alpha-tocopheryl-ω-methyl polyethyleneglycolyl-succinate (n = 44). 화학식 3의 화합물과 화학식 4의 화합물을 1,3-디사이클로헥실카보디이미드, N,N-디메틸-4-아미노피리딘 및 파라톨루엔술폰산으로 구성된 그룹중에서 선택된 축합제의 존재하에 에스테르화 반응시키는 것을 특징으로 하여, 제 1 항의 화학식 1 화합물을 제조하는 방법:Esterification of the compound of formula 3 with the compound of formula 4 in the presence of a condensing agent selected from the group consisting of 1,3-dicyclohexylcarbodiimide, N, N-dimethyl-4-aminopyridine and paratoluenesulfonic acid A process for preparing the compound of formula 1 according to claim 1 comprising: [화학식 3][Formula 3] [화학식 4][Formula 4] R-OHR-OH 상기 식에서, R은 제 1 항에서 정의한 바와 같다.Wherein R is as defined in claim 1. 삭제delete
KR10-2001-0029223A 2001-05-26 2001-05-26 Polyethoxylated alpha tocopherol ester derivatives and process for preparing the same KR100533304B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-2001-0029223A KR100533304B1 (en) 2001-05-26 2001-05-26 Polyethoxylated alpha tocopherol ester derivatives and process for preparing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2001-0029223A KR100533304B1 (en) 2001-05-26 2001-05-26 Polyethoxylated alpha tocopherol ester derivatives and process for preparing the same

Publications (2)

Publication Number Publication Date
KR20020090048A KR20020090048A (en) 2002-11-30
KR100533304B1 true KR100533304B1 (en) 2005-12-05

Family

ID=27706623

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2001-0029223A KR100533304B1 (en) 2001-05-26 2001-05-26 Polyethoxylated alpha tocopherol ester derivatives and process for preparing the same

Country Status (1)

Country Link
KR (1) KR100533304B1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024779A1 (en) * 1996-12-06 1998-06-11 Eastman Chemical Company Process for crystallizing d-alpha-tocopheryl succinate
US5869704A (en) * 1998-08-24 1999-02-09 Eastman Chemical Company Water-dispersible or water-soluble D-tocotrienol compounds and methods for making therefor
US5869703A (en) * 1997-07-12 1999-02-09 Pacific Corporation Nonionic vitamin E derivatives and a method for the preparation thereof, and polymeric ampliphilic vesicles made therefrom
WO1999033818A1 (en) * 1997-12-24 1999-07-08 Senju Pharmaceutical Co., Ltd. Vitamin e derivatives
JPH11246549A (en) * 1997-12-20 1999-09-14 Degussa Ag Production of alpha-tocopherol ester

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024779A1 (en) * 1996-12-06 1998-06-11 Eastman Chemical Company Process for crystallizing d-alpha-tocopheryl succinate
US5869703A (en) * 1997-07-12 1999-02-09 Pacific Corporation Nonionic vitamin E derivatives and a method for the preparation thereof, and polymeric ampliphilic vesicles made therefrom
JPH11246549A (en) * 1997-12-20 1999-09-14 Degussa Ag Production of alpha-tocopherol ester
WO1999033818A1 (en) * 1997-12-24 1999-07-08 Senju Pharmaceutical Co., Ltd. Vitamin e derivatives
US5869704A (en) * 1998-08-24 1999-02-09 Eastman Chemical Company Water-dispersible or water-soluble D-tocotrienol compounds and methods for making therefor

Also Published As

Publication number Publication date
KR20020090048A (en) 2002-11-30

Similar Documents

Publication Publication Date Title
JP4163746B2 (en) Use of dioxomorpholine to combat endoparasites, novel dioxomorpholines and methods for their production
JP4719160B2 (en) Florfenicol prodrug with improved water solubility
JP2002512226A (en) Substituted 2-oxo-alkanoic acid- [2- (indol-3-yl) -ethyl] amide
KR100428702B1 (en) Feed additive compositions for animals comprising polyethoxylated alpha tocopherol ester derivatives
US3493572A (en) Process for producing quinoxaline-di-n-oxides
KR100533304B1 (en) Polyethoxylated alpha tocopherol ester derivatives and process for preparing the same
JPS6219557A (en) Aryl ethanol hydroxylamine, manufacture and use for promoting production
US4100284A (en) 1,4-Dioxo- and 4-oxoquinoxaline-2-carboxaldehyde sulfonylhydrazones and certain derivatives thereof
FI59405B (en) METHOD OF FRAMSTATION OF METHYL-3- (2-QUINOXALYNYLMETHYLENE)-CARBARZATE-N1, N4-DIOXIDE
FI59404B (en) PROCEDURE FOR FRAMSTATION OF METHYL-3- (2-QUINOXALINYLMETHYLENE) CARBACATE-N1, N4-DIOXIDE
JP2003514815A (en) Allyloxypropanololamine for improving livestock production
KR100450274B1 (en) Feed additive compositions for animals comprising polyethoxylated ascorbic acid derivatives
HU202841B (en) Process for producing compositions for enhancing productivity of animals containing pyridyl-ethanol-amine as active component and process for producing the active components
US3763162A (en) Transesterification of quinoxaline-2-carboxylic acid esters
HU196741B (en) Process for producing fodder additive increasing the efficiency of animal husbandry, as well as aryl ethanole amines usable as active ingredient
CA1315787C (en) Morpholine compounds and methods of use
CS465586A2 (en) Prostredek ke zvyseni uzitkovosti zvirat a zpusob vyroby ucinnych latek
US4950669A (en) Methods and compositions for promoting growth of animals
HU192273B (en) Fodder additive containing monosilylated amino-phenyl-ethyl-amine derivatives and process for producing monosilylated amino-phenyl-ethyl-amine derivatives
JP2003514801A (en) Indazolyloxypropanolamine for improving livestock production
US4753937A (en) Morpholine compounds and method of promoting animal growth
KR101380186B1 (en) Alkylsilylated vitamin E derivatives and antioxidant comprising the same
HU196416B (en) Process for production of derivatives of new amin-phenilethil-amin and fodder-additives containing thereof
US3818007A (en) Hydroxyalkyl esters of quinoxaline-di-n-oxide-2-carboxylic acid
US3980648A (en) Process for producing quinoxaline-di-N-oxides

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee